JP2021502065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502065A5 JP2021502065A5 JP2020524144A JP2020524144A JP2021502065A5 JP 2021502065 A5 JP2021502065 A5 JP 2021502065A5 JP 2020524144 A JP2020524144 A JP 2020524144A JP 2020524144 A JP2020524144 A JP 2020524144A JP 2021502065 A5 JP2021502065 A5 JP 2021502065A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 176
- 239000000427 antigen Substances 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 87
- 239000012634 fragment Substances 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 29
- 108700041144 Angiopoietin-Like Protein 8 Proteins 0.000 claims description 18
- 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims description 18
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 17
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 101000924544 Homo sapiens Angiopoietin-like protein 8 Proteins 0.000 claims description 6
- 238000008214 LDL Cholesterol Methods 0.000 claims description 6
- 102000050918 human ANGPTL8 Human genes 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940125753 fibrate Drugs 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 2
- 239000006014 omega-3 oil Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 description 10
- 229940079593 drug Drugs 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584637P | 2017-11-10 | 2017-11-10 | |
| US62/584,637 | 2017-11-10 | ||
| PCT/US2018/059734 WO2019094533A1 (en) | 2017-11-10 | 2018-11-08 | Angptl8-binding agents and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502065A JP2021502065A (ja) | 2021-01-28 |
| JP2021502065A5 true JP2021502065A5 (enExample) | 2022-01-06 |
| JP7291694B2 JP7291694B2 (ja) | 2023-06-15 |
Family
ID=66439014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524144A Active JP7291694B2 (ja) | 2017-11-10 | 2018-11-08 | Ａｎｇｐｔｌ８結合薬及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10774139B2 (enExample) |
| EP (1) | EP3749691A4 (enExample) |
| JP (1) | JP7291694B2 (enExample) |
| CN (1) | CN111315775A (enExample) |
| AU (1) | AU2018366122A1 (enExample) |
| CA (1) | CA3080148A1 (enExample) |
| WO (1) | WO2019094533A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10071139B2 (en) | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
| WO2019126194A1 (en) * | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN110694067A (zh) * | 2019-11-06 | 2020-01-17 | 首都医科大学附属北京安贞医院 | 一种抑制血管生成素样蛋白8的物质的应用 |
| CN119367545B (zh) * | 2025-01-02 | 2025-04-08 | 山东第一医科大学(山东省医学科学院) | 靶向干预ANGPTL8 mRNA在制备治疗高同型半胱氨酸血症药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2425738T3 (es) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| WO2011084714A2 (en) * | 2009-12-17 | 2011-07-14 | Biogen Idec Ma Inc. | STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF |
| AU2012267492A1 (en) | 2011-06-10 | 2014-01-09 | President And Fellows Of Harvard College | Modulation of pancreatic beta cell proliferation |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| US10259863B2 (en) | 2013-01-11 | 2019-04-16 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| JP2016513098A (ja) * | 2013-02-07 | 2016-05-12 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ） |
| CA2925393C (en) * | 2013-10-11 | 2023-03-07 | Dimiter Dimitrov | Tem8 antibodies and their use |
| US10071139B2 (en) | 2014-10-03 | 2018-09-11 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| LT3439689T (lt) * | 2016-04-08 | 2021-11-10 | Regeneron Pharmaceuticals, Inc. | Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi |
| EA201991203A1 (ru) | 2016-11-17 | 2019-10-31 | Способы лечения ожирения антителами к angptl8 | |
| CA3080148A1 (en) | 2017-11-10 | 2019-05-16 | Ngm Biopharmaceuticals, Inc. | Angptl8-binding agents and methods of use thereof |
-
2018
- 2018-11-08 CA CA3080148A patent/CA3080148A1/en active Pending
- 2018-11-08 EP EP18877271.9A patent/EP3749691A4/en not_active Withdrawn
- 2018-11-08 AU AU2018366122A patent/AU2018366122A1/en not_active Abandoned
- 2018-11-08 US US16/184,548 patent/US10774139B2/en not_active Expired - Fee Related
- 2018-11-08 CN CN201880070810.0A patent/CN111315775A/zh active Pending
- 2018-11-08 JP JP2020524144A patent/JP7291694B2/ja active Active
- 2018-11-08 WO PCT/US2018/059734 patent/WO2019094533A1/en not_active Ceased
-
2020
- 2020-08-18 US US16/996,623 patent/US11566067B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502065A5 (enExample) | ||
| JP2025179073A (ja) | 二重特異性抗体 | |
| JP2022101693A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| JP2020152735A5 (enExample) | ||
| JP2020099324A5 (enExample) | ||
| JP2020002172A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| IL268745A (en) | Antibody drug conjugates (adc) that bind to 158p1d7 proteins | |
| JP2009525764A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017522861A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| JP2016538318A5 (enExample) | ||
| JP2016531915A5 (enExample) | ||
| JP2016536020A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| CN106573983B (zh) | 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段 | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2011207882A5 (enExample) | ||
| JP2016520520A5 (enExample) | ||
| JP2021508707A5 (enExample) |